Melanoma Clinical Trials

Showing 1141-1160 of 1,477 trials

Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

NCT02200562

Phase I/II study of ipilimumab concurrent ipilimumab and dabrafenib as first line treatment in Stage III or IV melanoma. Assessing safety of Ipilimumab and dabrafenib in combination. Also, assessing disease control rates.

Stage III or IV Melanoma

University of Utah6 participantsStarted Dec 2014

Salt Lake City, Utah, United States

COMPLETEDPhase 2

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

NCT00450372

RATIONALE: Pegylated arginine deiminase may stop the growth of tumor cells by taking away an amino acid needed for cell growth. PURPOSE: This phase II trial is studying how well pegylated arginine deiminase works in treating patients with metastatic melanoma that cannot be removed by surgery.

Melanoma (Skin)

University of Miami38 participantsStarted Jun 2004

Miami, Florida, United States

WITHDRAWNPhase 2

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

NCT02400385

This will be a phase II trial of the combination of sunitinib and nivolumab in patients with advanced, measurable, metastatic melanoma who harbor mutations in the KIT gene in their tumors. It is a multi-center trial using the FDA-approved doses of both sunitinib and nivolumab. Sunitinib will be provided by Pfizer. Endpoint is RECIST response rate and PFS.

Melanoma

California Pacific Medical Center Research InstituteStarted Oct 2014

San Francisco, California, United States

Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Related Searches

Melanoma Perception and Health Literacy in People of Color

18F-Labeled Picolinamide PET Imaging of Melanoma Diagnosis

Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

Vaccine Therapy in Treating Patients With Advanced Melanoma

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Disulfiram in Patients With Metastatic Melanoma

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

Prospective Measurement of Post-Treatment Lymphedema

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma